Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

Aditya H. Gaur, Edmund V. Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A. Marzinke, Cynthia McCoig, Rodica M. Van Solingen-Ristea, Sisinyana Ruth Mathiba, Adeola Adeyeye, Jack Moye, Barbara Heckman, Elizabeth D. Lowenthal, S. M. Ward, Ryan O. Milligan, Pearl Samson, Brookie M. Best, Conn Harrington, Susan L. Ford, Jenny Huang, Herta Crauwels, Kati Vandermeulen, Allison L. Agwu, Christiana Smith-Anderson, Andrés Camacho-González, Pradthana Ounchanum, Jared L. Kneebone, Ellen Townley, Carolyn Bolton‐Moore, Sarah Buisson, S.Y. Amy Cheung, Vasiliki Chounta, Isabelle Déprez, Alicia C. Desmond, Kelong Han, Sherika Hanley, Yu-Wei Lin, Faeezah Patel, Mary E. Paul, Gilly Roberts, Kyle Whitson, Sara Zabih